right-on Threes! I second that perspective.
The institutions represented by NCCN are some of the most prestigious and advanced global bodies that partner on development of medicines, run trials and treat patients.
I'm very confused reading some posts that look at this as an act of desperation or hedging of bets. Getting a product to be accepted into NCCN for evaluation and broad testing is a privilege - not an entitlement. The people who do the work are scientists, the best in the world, who do not take their work lightly and absolutely do not see themselves as assembly line workers just pushing the next product through its paces while collecting a salary. They spend their lives looking for cures and ways to help fight disease. They are never the dumpling grounds for a company's molecule desperately looking for a problem to solve...
So - yes. This provides both an insurance policy for high integrity and access to the basket of modern meds that various pharmas and research institutions have deployed or are in the process of evaluating. It's the best federated model one can get where the best expertise in drug development and testing comes together with the broadest range of combo candidates to see what can be brought to bear.
It's all pointing to the strategy of filing for Lung with Bavi/Doce closely followed by multiple filing for multiple indications through the various collaborations - should they produce the results we hope.
Best,
MH
News 
Market Data 
Discover 
